What SABR dose-fractionation would you use when treating an oligometastatic site in the femur or weight-bearing acetabulum?

This is a very good question. We only excluded femoral sites from COMET out of an abundance of caution, not because of any evidence suggesting fractures in this location.

We were worried that a couple of fractures would not only cause harm, but would also end the trial, particularly as they can lead ...